following an abbreviated submission:
zanubrutinib (Brukinsa®) is accepted for restricted use within NHSScotland.
Indication under review: as monotherapy for the treatment of adult patients with chronic lymphocytic leukaemia (CLL).
SMC restriction: For adults with CLL in whom chemo-immunotherapy is unsuitable.
Zanubrutinib offers an additional treatment choice in the therapeutic class of Bruton tyrosine kinase inhibitor in this setting.
Another medicine within this therapeutic class has been accepted via the end-of-life and orphan medicine process.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Download detailed advice254KB (PDF)
- Medicine name:
- zanubrutinib (Brukinsa)
- SMC ID:
As monotherapy for the treatment of adult patients with chronic lymphocytic leukaemia (CLL)
- Pharmaceutical company
- BeiGene UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Date advice published
- 09 October 2023